ATXS · As filed with the SEC
Astria Therapeutics income statement, by fiscal year
The statement as Astria Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations · USD, except per-share amounts
| USD, except per-share amounts | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 |
|---|---|---|
| Operating expenses: | ||
| Research and development | 77,106,000 | 42,127,000 |
| General and administrative | 34,452,000 | 25,704,000 |
| Acquired in-process research and development | — | 15,199,000 |
| Total operating expenses | 111,558,000 | 83,030,000 |
| Loss from operations | (111,558,000) | (83,030,000) |
| Other income (expense): | ||
| Interest and investment income | 17,360,000 | 10,201,000 |
| Other expense, net | (62,000) | (62,000) |
| Total other income, net | 17,298,000 | 10,139,000 |
| Net loss | (94,260,000) | (72,891,000) |
| Net loss per share attributable to common shareholders - basic | (1.68) | (2.42) |
| Net loss per share attributable to common shareholders - diluted | (1.68) | (2.42) |
| Weighted-average common shares outstanding used in net loss per share - basic | 56,161,249 | 30,123,316 |
| Weighted-average common shares outstanding used in net loss per share - diluted | 56,161,249 | 30,123,316 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.